Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Rockville, Maryland and currently employs 29 full-time employees. The company went IPO on 2021-02-04. The firm's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The firm is also completing a Phase I/II trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Its TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Its programs include Solnerstotug (SNS-101), SNS-102, SNS-103, and SNS-201. Solnerstotug is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1.
How did SNSE's recent EPS compare to expectations?
The most recent EPS for Sensei Biotherapeutics Inc is $, expectations of $-0.63.
How did Sensei Biotherapeutics Inc SNSE's revenue perform in the last quarter?
Sensei Biotherapeutics Inc revenue for the last quarter is $
What is the revenue estimate for Sensei Biotherapeutics Inc?
According to 3 of Wall street analyst, the revenue estimate of Sensei Biotherapeutics Inc range from $0.0 to $0.0
What's the earning quality score for Sensei Biotherapeutics Inc?
Sensei Biotherapeutics Inc has a earning quality score of B+/45.225716. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Sensei Biotherapeutics Inc report earnings?
Sensei Biotherapeutics Inc next earnings report is expected in 2026-08-05
What are Sensei Biotherapeutics Inc's expected earnings?
Sensei Biotherapeutics Inc expected earnings is $0.0, according to wall-street analysts.
Did Sensei Biotherapeutics Inc beat earnings expectations?
Sensei Biotherapeutics Inc recent earnings of $ expectations.